Trial Profile
Feasibility study of combination therapy with S-1 plus irinotecan in patients with EGFR positive KRAS mutation type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine, bevacizumab
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 24 Jan 2013 New trial record